Genentech licenses IRAK4 inhibitors from Nimbus

Computational chemistry company Nimbus Therapeutics LLC (Cambridge, Mass.) granted the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) an exclusive, worldwide license to develop and commercialize small molecule inhibitors of interleukin-1 receptor-associated kinase 4 ( IRAK4).

Neither Genentech nor Nimbus would name specific programs or indications the partners will study, but Genentech spokesperson Nadine Pinell told BioCentury that company's "primary interest is in immunological disorders." ...